Live Conference Coverage Medcity Converge 2018 Philadelphia: Clinical Trials and Mega Health Mergers
Reporter: Stephen J. Williams, PhD
1:30 – 2:15 PM Clinical Trials 2.0
The randomized, controlled clinical trial is the gold standard, but it may be time for a new model. How can patient networks and new technology be leveraged to boost clinical trial recruitment and manage clinical trials more efficiently?
Moderator: , Chief Product Officer, Thread @johnreites
Speakers:
, Chief of Cancer Services , Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital
, Founder, Medable @LongmireMD
, Medical Oncologist and Researcher, Ohio State University Comprehensive Cancer Center @OSUCCC_James
Michele: Medable is creating a digital surrogate biomarker for short term end result for cardiology clinical trials as well as creating a virtual site clinical trial design (independent of geography)
Sameek: OSU is developing RNASeq tests for oncogenic fusions that are actionable
John: ability to use various technologies to conduct telehealth and tele-trials. So why are we talking about Clinical Trials 2.0?
Andrew: We are not meeting many patients needs. The provider also have a workload that prevents from the efficient running of a clinical trial.
Michele: Personalized medicine: what is the framework how we conduct clinical trials in this new paradigm?
Sameek: How do we find those rare patients outside of a health network? A fragmented health system is hurting patient recruitment efforts.
Wout: The Christmas Tree paradigm: collecting data points based on previous studies may lead to unnecessary criteria for patient recruitment
Sameek: OSU has a cancer network (Orion) that has 95% success rate of recruitment. Over Orion network sequencing performed at $10,000 per patient, cost reimbursed through network. Network helps pharma companies find patients and patients to find drugs
Wout: reaching out to different stakeholders
John: what he sees in 2.0 is use of tech. They took 12 clinic business but they integrated these sites and was able to benefit patient experience… this helped in recruitment into trials. Now after a patient is recruited, how 2.0 model works?
Sameek: since we work with pharma companies, what if we bring in patients from all over the US. how do we continue to take care of them?
Andrew: utilizing a technology is critically important for tele-health to work and for tele-clinical trials to work
Michele: the utilization of tele-health by patients is rather low.
Wout: We are looking for insights into the data. So we are concentrated on collecting the data and not decision trees.
John: What is a barrier to driving Clinical Trial 2.0?
Andrew: The complexity is a barrier to the patient. Need to show the simplicity of this. Need to match trials within a system.
Saleem: Data sharing incentives might not be there or the value not recognized by all players. And it is hard to figure out how to share the data in the most efficient way.
Wout: Key issue when think locally and act globally but healthcare is the inverse of this as there are so many stakeholders but that adoption by all stakeholders take time
Michele: accessibility of healthcare data by patients is revolutionary. The medical training in US does not train doctors in communicating a value of a trial
John: we are in a value-driven economy. You have to give alot to get something in this economy. Final comments?
Saleem: we need fundamental research on the validity of clinical trials 2.0.
Wout: Use tools to mine manually but don’t do everything manually, not underlying tasks
Andrew: Show value to patient
2:20-3:00 PM CONVERGEnce on Steroids: Why Comcast and Independence Blue Cross?
This year has seen a great deal of convergence in health care. One of the most innovative collaborations announced was that of Cable and Media giant Comcast Corporation and health plan Independence Blue Cross. This fireside chat will explore what the joint venture is all about, the backstory of how this unlikely partnership came to be, and what it might mean for our industry.
sponsored by Independence Blue Cross @IBX
Moderator: , Managing Director Strategic Innovation Portfolio, Independence Blue Cross @IBX
Speakers:
, VP, Strategic Development, Comcast
, SVP, Chief Information Officer, Independence Blue Cross
Comcast and Independence Blue Cross Blue Shield are teaming together to form an independent health firm to bring various players in healthcare onto a platform to give people a clear path to manage their healthcare. Its not just about a payer and information system but an ecosystem within Philadelphia and over the nation.
Michael: About 2015 at a health innovation conference they came together to produce a demo on how they envision the future of healthcare.
Marc: When we think of a customer we think of the household. So we thought about aggregating services to people in health. How do people interact with their healthcare system?
What are the risks for bringing this vision to reality?
Michael: Key to experience is how to connect consumer to caregiver.
How do we aggregate the data, and present it in a way to consumer where it is actionable?
How do we help the patient to know where to go next?
Marc: Concept of ubiquity, not just the app, nor asking the provider to ask patient to download the app and use it but use our platform to expand it over all forms of media. They did a study with an insurer with metabolic syndrome and people’s viewing habits. So when you can combine the expertise of IBX and the scale of a Comcast platform you can provide great amount of usable data.
Michael: Analytics will be a prime importance of the venture.
Tom: We look at lots of companies that try to pitch technologies but they dont understand healthcare is a human problem not a tech problem. What have you learned?
Marc: Adoption rate of new tech by doctors is very low as they are very busy. Understanding the clinicians workflow is important and how to not disrupt their workflow was humbling for us.
Michael: The speed at which big tech companies can integrate and innovate new technologies is very rapid, something we did not understand. We want to get this off the ground locally but want to take this solution national and globally.
Marc: We are not in competition with local startups but we are looking to work with them to build scale and operability so startups need to show how they can scale up. This joint venture is designed to look at these ideas. However this will take a while before we open up the ecosystem until we can see how they would add value. There are also challenges with small companies working with large organizations.
Please follow on Twitter using the following #hashtags and @pharma_BI
#MCConverge
#cancertreatment
#healthIT
#innovation
#precisionmedicine
#healthcaremodels
#personalizedmedicine
#healthcaredata
And at the following handles:
@pharma_BI
@medcitynews
Please see related articles on Live Coverage of Previous Meetings on this Open Access Journal
https://pharmaceuticalintelligence.com/press-coverage/
Like this:
Like Loading...
Read Full Post »